Overview

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Status:
Withdrawn

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).

Phase:

Phase 2

Details

Lead Sponsor:

Matinas BioPharma Nanotechnologies, Inc.

Treatments:

Amphotericin B
Liposomal amphotericin B